+Compare
APLS
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
5.07B

APLS Apellis Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of therapeutics and drug delivery technologies to address chronic inflammatory diseases

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for APLS with price predictions
08:00 PM EDT Sep 26, 2023

APLS's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Indicator for APLS moved out of overbought territory on September 21, 2023. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 instances where the indicator moved out of the overbought zone. In of the 40 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 27, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on APLS as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for APLS turned negative on September 26, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

APLS broke above its upper Bollinger Band on September 18, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

APLS moved above its 50-day moving average on September 14, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for APLS crossed bullishly above the 50-day moving average on September 14, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APLS advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 294 cases where APLS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. APLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.728) is normal, around the industry mean (22.662). P/E Ratio (0.000) is within average values for comparable stocks, (131.532). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.103). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (26.525) is also within normal values, averaging (306.452).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 407B. NVO holds the highest valuation in this group at 407B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was 13%, and the average quarterly price growth was 34%. SLNO experienced the highest price growth at 404%, while IMVIQ experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 126% and the average quarterly volume growth was 75%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

APLS is expected to report earnings to rise 12.75% to -114 cents per share on November 06

Apellis Pharmaceuticals APLS Stock Earnings Reports
Q3'23
Est.
$-1.15
Q2'23
Beat
by $0.34
Q1'23
Missed
by $0.10
Q4'22
Beat
by $0.01
Q3'22
Missed
by $0.31
The last earnings report on July 31 showed earnings per share of -101 cents, beating the estimate of -136 cents. With 9.36M shares outstanding, the current market capitalization sits at 5.07B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics and drug delivery technologies to address chronic inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Distributors
Address
100 Fifth Avenue
Phone
+1 617 977-5700
Employees
767
Web
https://www.apellis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ADPV24.110.42
+1.75%
Adaptiv™ Select ETF
FAUG37.33-0.01
-0.03%
FT Cboe Vest US Equity Buffer ETF Aug
PTBD19.46-0.01
-0.05%
Pacer Trendpilot US Bond ETF
SPAB24.28-0.09
-0.37%
SPDR® Portfolio Aggregate Bond ETF
GLDB18.09-0.40
-2.16%
Strategy Shares Gold-Hedged Bond ETF

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with NOVNQ. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then NOVNQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-10.06%
NOVNQ - APLS
52%
Loosely correlated
-25.07%
QNRX - APLS
48%
Loosely correlated
-1.85%
CYTK - APLS
45%
Loosely correlated
-0.27%
MDGL - APLS
44%
Loosely correlated
+1.70%
KRYS - APLS
42%
Loosely correlated
+0.29%
More

Groups containing APLS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-10.06%
therapeutics
(undefined stocks)
33%
Loosely correlated
-0.25%
diseases
(undefined stocks)
27%
Poorly correlated
+0.22%
drugs
(undefined stocks)
19%
Poorly correlated
+0.51%
medical devices
(undefined stocks)
12%
Poorly correlated
-1.04%